IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
28.13
-0.19 (-0.67%)
May 11, 2026, 4:00 PM EDT - Market closed
IDEAYA Biosciences Revenue
IDEAYA Biosciences had revenue of $6.56M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $225.27M, up 3,118.14% year-over-year. In the year 2025, IDEAYA Biosciences had annual revenue of $218.71M with 3,024.43% growth.
Revenue (ttm)
$225.27M
Revenue Growth
+3,118.14%
P/S Ratio
10.97
Revenue / Employee
$1,553,586
Employees
145
Market Cap
2.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 218.71M | 211.71M | 3,024.43% |
| Dec 31, 2024 | 7.00M | -16.39M | -70.07% |
| Dec 31, 2023 | 23.39M | -27.55M | -54.08% |
| Dec 31, 2022 | 50.93M | 22.99M | 82.28% |
| Dec 31, 2021 | 27.94M | 8.40M | 43.01% |
| Dec 31, 2020 | 19.54M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 670.00M |
| Tarsus Pharmaceuticals | 535.08M |
| Nanobiotix | 38.27M |
| Relay Therapeutics | 10.68M |
| Immunome | 6.94M |
| Celldex Therapeutics | 865.00K |
IDYA News
- 4 days ago - Ideaya Biosciences price target lowered to $50 from $52 at Mizuho - TheFly
- 7 days ago - Ideaya Biosciences reports Q1 EPS ($1.11), consensus (98c) - TheFly
- 7 days ago - IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update - PRNewsWire
- 11 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 12 days ago - Ideaya Biosciences announces darovasertib combination NDA to be reviewed by FDA - TheFly
- 12 days ago - IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program - PRNewsWire
- 20 days ago - IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma - PRNewsWire
- 27 days ago - Ideaya Biosciences price target raised to $58 from $52 at Wedbush - TheFly